Skip to content

Clinical Validation of an Immunocytochemistry Method Using MARS1

Clinical Validation of an Immunocytochemistry Method Using Antibody of Methionyl-tRNA Synthetase (MARS1) in the Bile Duct Cancer Cell; Multicenter Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04759794
Acronym
MARS1
Enrollment
55
Registered
2021-02-18
Start date
2021-02-04
Completion date
2023-02-03
Last updated
2025-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bile Duct Obstruction, Extrahepatic

Keywords

bile duct obstruction, extrahepatic, cytology, aminoacyl-tRNA synthetases

Brief summary

The sensitivity of brushing cytology used to distinguish the cause of biliary strictures is low and clinical usefulness is not secured. The aim of this study was to validate the clinical usefulness of a new differential staining method for cytology which is difficult to differentiate by the conventional staining method using biliary cancer-related protein expressed only in bile duct cancer.

Detailed description

Hypothesis: The statistical significance of new staining method using aminoacyl-tRNA synthetases (ARSs) group in normal bile duct cells and the bile duct cancer cells collected by endoscopic retrograde pancreaticoduodenoscopy (ERCP) will be compared to prove the usefulness of the new staining method. Clinical study design: The bile duct cytology will be obtained by brushing cytology using ERCP in patients with biliary stenosis. The expression of ARSs in the brushing cytology will be evaluated by a new staining method and compare with the results of the conventional cytology staining method including Papanicolaou staining. Immunofluorescence or immunocytochemistry staining will be performed to differentiate the presence of the tumor. The sensitivity and specificity of the new staining method will be compared with the conventional staining method and its usefulness be confirmed.

Interventions

DIAGNOSTIC_TESTCytology staining

Two stainings will be performed in cytology specimens obtained from the same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography 1. conventional cytology staining method 2. new cytology staining method using the antibody of aminoacyl-tRNA synthetases

Sponsors

Gangnam Severance Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

The conventional staining method and new staining method will be performed in cytology specimens obtained from the same patient.

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with biliary cancer confirmed by imaging (CT, MRI, positron emission tomography) * Patients with bile duct cancer diagnosed using brushing cytology by endoscopic retrograde pancreaticoduodenoscopy * Patients who underwent surgical treatment with biliary cancer * Patients with bile duct stenosis

Exclusion criteria

* Minors under the age of 19, vulnerable subjects such as illiteracy * Necrotic specimens * Samples with non-diagnostic cytology results and insufficient cells for further evaluation * Samples classified as neoplastic (benign or other) * Patient with cholangitis in the bile duct

Design outcomes

Primary

MeasureTime frameDescription
The usefulness of new staining method1 yearThe sensitivity, specificity, positive predictive value, negative predictive value and accuracy of new staining method will be compared with th conventional Pap staining of brushing cytology specimens.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026